Dorsey & Whitney Trust CO LLC Reduces Stock Holdings in AbbVie Inc. $ABBV

Dorsey & Whitney Trust CO LLC decreased its stake in AbbVie Inc. (NYSE:ABBV) by 14.5% in the fourth quarter, Holdings Channel.com reports. The firm owned 27,939 shares of the company’s stock after selling 4,746 shares during the period. Dorsey & Whitney Trust CO LLC’s holdings in AbbVie were worth $6,384,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of ABBV. Chelsea Counsel Co. purchased a new position in shares of AbbVie in the 3rd quarter worth approximately $26,000. Westend Capital Management LLC purchased a new position in AbbVie during the 4th quarter valued at $29,000. Texas Capital Bancshares Inc TX purchased a new position in AbbVie during the 3rd quarter valued at $31,000. Legacy Wealth Managment LLC ID boosted its holdings in AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after acquiring an additional 73 shares during the period. Finally, WestEnd Advisors LLC boosted its holdings in AbbVie by 160.4% during the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on ABBV shares. Evercore set a $235.00 price objective on AbbVie in a report on Friday, May 15th. William Blair restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Barclays started coverage on AbbVie in a report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price objective for the company. Piper Sandler boosted their price objective on AbbVie from $294.00 to $298.00 and gave the company an “overweight” rating in a report on Thursday, May 14th. Finally, Royal Bank Of Canada started coverage on AbbVie in a report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and a consensus target price of $253.43.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s migraine drug was cleared for use in migraine attacks on the NHS, a sign of broader adoption potential that could support future sales growth. AbbVie’s migraine drug cleared for migraine attacks on NHS
• Positive Sentiment: Allergan Aesthetics, an AbbVie company, highlighted new consumer research in its aesthetics business, reinforcing ongoing brand visibility and interest in its aesthetics portfolio. Allergan Aesthetics Releases ‘The Aesthetics Evolution: What Consumers Really Want’
• Neutral Sentiment: AbbVie presented at Goldman Sachs’ healthcare conference, which typically provides investors with updates on strategy and pipeline but did not include a major new catalyst in the headline. AbbVie Inc. (ABBV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: AbbVie was mentioned in “final trades” and “below fair value”/discount-stock roundups, which may keep valuation-focused investors interested but are not company-specific operational news. Final trades: AbbVie, Morgan Stanley, Shake Shack and the CBOE
• Negative Sentiment: AbbVie received a Complete Response Letter from the FDA for TrenibotE, its fast-acting neurotoxin candidate. The agency cited manufacturing-related issues and raised no safety or efficacy concerns, but the delay still pushes back a potential new product launch. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE
• Negative Sentiment: AbbVie also terminated its deal with I-Mab to develop a cancer drug, removing a potential pipeline opportunity and signaling a setback in its oncology collaboration strategy. AbbVie terminates deal with I-Mab to develop cancer drug

AbbVie Trading Down 0.1%

Shares of ABBV stock opened at $225.16 on Thursday. AbbVie Inc. has a twelve month low of $181.73 and a twelve month high of $244.81. The stock has a market capitalization of $397.82 billion, a price-to-earnings ratio of 110.92, a P/E/G ratio of 0.69 and a beta of 0.32. The stock has a fifty day simple moving average of $210.64 and a two-hundred day simple moving average of $219.09.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. During the same period in the prior year, the business earned $2.46 EPS. The business’s revenue for the quarter was up 12.4% compared to the same quarter last year. Research analysts predict that AbbVie Inc. will post 14.3 EPS for the current fiscal year.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.